Browsing Tag
Regenerative Medicine
27 posts
Is this the biomarker breakthrough Longeveron Inc. needs to reach Phase 3?
Can biomarker-linked response boost laromestrocel’s Phase 3 prospects? Explore regulatory, financial, and industry implications.
Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data
Find out why Longeveron Inc.’s CEO appointment comes at a critical clinical and financial moment and what it could mean for investors and regenerative medicine.
BioStem Technologies (OTC: BSEM) acquires BioTissue wound care unit to expand hospital market presence
BioStem acquires BioTissue’s wound care business for $15M, gaining GPO access, sales force, and acute care exposure. Find out what this means for growth.
Emmecell names ex-AbbVie executive Ramin Valian as CEO to lead cell therapy platform
Emmecell names Ramin Valian as CEO to guide its magnetic cell delivery platform toward pivotal trials. Find out what this leadership shift means for the industry.
Could this tiny biotech help fix transplant logistics? LifeNet Health thinks so
LifeNet Health acquires Tissue Testing Technologies to scale cryopreservation in transplants. Find out how this deal reshapes regenerative medicine.
FDA nod sends Organogenesis shares higher as ReNu eyes BLA filing for knee osteoarthritis pain
Find out how Organogenesis’ FDA alignment clears the path for a ReNu BLA filing in knee osteoarthritis pain and why investors are paying attention now.
Biorep achieves first successful independent PRISM system use in islet isolation
Biorep’s PRISM system achieves first independent islet isolation milestone at SNBTS. Discover how it’s shaping the future of lab automation.
From tissue to biologic: AVANCE’s FDA clearance marks a turning point for nerve injury treatment
Axogen gets FDA biologics nod for AVANCE nerve graft, unlocking 12 years of exclusivity. Find out how this reshapes nerve repair in 2026 and beyond.
HMP Global acquires Music City SCALE in aesthetics education expansion
HMP Global acquires Music City SCALE to expand its aesthetics and dermatology education platform. Discover how this reshapes skin health learning in 2025.
RMTG and CELLGENIC unveil pre-loaded peptide pens — the next frontier in regenerative therapy
Find out how RMTG’s CELLGENIC is expanding into device-enabled regenerative therapy with its new peptide-pen line introduced at the Cancún global summit.